XCOR Therapeutics is a Baltimore-based medical device company that is revolutionizing the treatment of hypercarbic respiratory failure. They are developing the first commercially available extracorporeal CO2 removal device that utilizes ultra-low-blood flow. This condition, which is caused by chronic diseases or acute trauma, leads to an accumulation of CO2 in the blood, resulting in difficulty breathing and reduced quality of life for millions of people globally.

Unlike current medical therapies, XCOR's solution is accessible, affordable, and effective. Their device can be used by more clinicians and hospitals worldwide, eliminating the need for highly specialized training. Additionally, it offers a cost-effective therapy that can be utilized outside of ICUs, benefiting patients, hospitals, and healthcare systems.

XCOR's core technology, a patent-pending medical device, allows physicians to remove excess CO2 from symptomatic lung failure patients. It is designed for ease of use, widespread adoption, and rapid deployment. With a team of experienced professionals and a commitment to innovation, XCOR Therapeutics is transforming the landscape of respiratory care